Transaction #2541 · Form 4 · 0001193125-25-251874
4D Molecular Therapeutics, Inc. · Exercise / conversion · Common Stock
4D Molecular Therapeutics, Inc. · Transacted October 24, 2025 · Filed October 27, 2025
What does this filing report?
An SEC Form 4 filing for 4D Molecular Therapeutics, Inc. records an exercise / conversion involving Common Stock on October 24, 2025. The reported quantity was 1,084. The filing date is October 27, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company CIK
- 0001650648
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 1,084
- Reported price
- 6.49
- Reference value
- 7,035.16
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 6,272
- Ownership description
- Not reported
- SEC acceptance time
- Oct 27, 2025, 6:19 PM EDT
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Bizily Scott ↗
Chief Legal Officer
CIK 0001920738
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- F2
- The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.